3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Molecular Gateway to Advanced Gastric Acid Secretion and Neuroinflammation Research

Introduction

The study of gastric acid secretion and the underlying molecular pathways remains central to understanding and treating gastric acid-related disorders such as peptic ulcer disease and gastroesophageal reflux. In recent years, focus has expanded to the intersection of gastrointestinal and neurological health, including the gut–liver–brain axis and its role in systemic diseases. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845), available from APExBIO, has established itself as a highly selective H+,K+-ATPase inhibitor with robust antiulcer activity for research applications. Uniquely, this article explores not only the compound's established role as a gastric acid secretion inhibitor but also its translational implications in neuroinflammation and gut–brain axis research—an approach that expands upon previous laboratory-centered and protocol-driven discussions in the field.

Chemical Profile and Handling Considerations

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is a solid with a molecular weight of 345.42 Da and the formula C₁₇H₁₉N₃O₃S. The compound is virtually insoluble in water and ethanol but dissolves readily in DMSO at concentrations ≥17.27 mg/mL. Its high purity (~98%, HPLC/NMR-verified) ensures reliable, reproducible data, and it should be stored at -20°C for optimal stability, avoiding long-term solution storage. These features make it not only a potent inhibitor but also a practical and robust tool for mechanistic studies and advanced assay designs.

Mechanism of Action: Targeting the H+,K+-ATPase Signaling Pathway

The primary mode of action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is the inhibition of the gastric H+,K+-ATPase (proton pump) in parietal cells, a critical final step in the acid secretion pathway. By blocking this enzyme, the compound markedly reduces gastric acid output, thereby exerting powerful antisecretory and antiulcer effects. Its IC₅₀ for H+,K+-ATPase inhibition is 5.8 μM, while its inhibitory concentration for histamine-induced acid formation is a notably low 0.16 μM, positioning it among the most potent agents for studying the proton pump inhibition pathway.

This mechanism is especially valuable for dissecting the H+,K+-ATPase signaling pathway in cellular and animal models. In contrast to general proton pump inhibitors like IC omeprazole, A2845’s well-defined potency and selectivity enable researchers to probe subtle regulatory features and downstream effects, paving the way for advanced antiulcer activity studies and the creation of highly controlled peptic ulcer disease models.

Expanding Horizons: From Gastric Acid Secretion Research to the Gut–Brain Axis

While most existing literature—including protocol-focused guides and laboratory case studies—emphasize the role of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide in classical gastric acid secretion research, this article uniquely examines its relevance in the context of the gut–liver–brain axis and neuroinflammation.

Gut–Liver–Brain Axis and Neuroinflammation

Emerging findings, such as those by Kong et al. (European Journal of Neuroscience, 2025), underscore the importance of the gut microbiota and its metabolites in modulating neuroinflammation in chronic hepatic encephalopathy (HE). In their study, [18F]PBR146 PET imaging revealed region-specific neuroinflammatory changes in rat models subjected to bile duct ligation, with Bifidobacterium administration alleviating neuroinflammation while fecal microbiota transplantation did not. These insights highlight the interplay between gut-derived signals, hepatic function, and central nervous system (CNS) inflammation.

Disorders of gastric acid secretion and the use of potent inhibitors like A2845 can significantly alter gut microbial ecology, with potential systemic and neurological consequences. By enabling precise control over gastric acid output, A2845 provides an advanced tool for teasing apart the contribution of gastric acid modulation to the gut–brain axis and for modeling disease states that bridge gastroenterology and neuroscience.

Comparative Analysis: A2845 Versus Classical and Next-Generation Inhibitors

Conventional H+,K+-ATPase inhibitors such as IC omeprazole have been the cornerstone of both clinical management and laboratory research for gastric acid-related disorders. However, their broad mechanism of action and metabolic liabilities can confound in-depth mechanistic investigations. In contrast, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide provides:

• Significantly higher selectivity and potency at the target enzyme
• Superior solubility profile in DMSO for in vitro and in vivo models
• Purity and stability suitable for sensitive assay systems and longitudinal studies

Whereas the article "3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is a high-purity, potent H+,K+-ATPase inhibitor validated for gastric acid secretion and antiulcer activity research" provides a data-driven synthesis regarding purity and protocol, this piece delves deeper into the translational and systemic implications, focusing on how such chemical precision enables new experimental paradigms—especially at the intersection of gastrointestinal and neurological research.

Advanced Applications in Disease Modeling and Translational Research

Peptic Ulcer Disease Models

Thanks to its defined IC₅₀ values and reliable pharmacological profile, A2845 is particularly suited for the development of peptic ulcer disease models. Its use allows for:

• Controlled induction and modulation of gastric acid secretion for pathogenesis studies
• Evaluation of antiulcer agents and combinatorial therapies in preclinical settings
• Assessment of the impact of acid modulation on gut microbial composition and systemic inflammation

Unlike previous articles that focus on actionable protocols or stepwise troubleshooting for gastric acid secretion research (see here), this article emphasizes how such models can be leveraged to study not only local gastric outcomes but also systemic effects—such as alterations in the gut–brain axis highlighted by recent neuroinflammation studies.

Translational Frontiers: From Gastric Disorders to CNS Disease

Recent research has revealed that chronic gastric acid suppression, whether by pharmaceuticals or genetic manipulation, can lead to shifts in the gut microbiome, increased risk of infections, and even changes in neurological function. By deploying a highly selective gastric acid secretion inhibitor like A2845, investigators can more precisely model these effects and dissect the causal pathways involved.

For instance, the study by Kong et al. (2025) demonstrates the utility of advanced imaging (e.g., [18F]PBR146 PET) to monitor neuroinflammation in vivo, enabling the integration of gastric, hepatic, and CNS endpoints in a unified experimental framework. This aligns with, but goes beyond, the vision established in "Translational Frontiers in Gastric Acid Secretion Research", by focusing on the specific role of precise chemical inhibition in elucidating system-wide disease mechanisms.

Best Practices for Experimental Design and Product Handling

To leverage the full potential of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide for advanced gastric acid secretion research or neuroinflammatory disease models, consider the following best practices:

• Prepare fresh DMSO stock solutions for each experiment, avoiding long-term storage in solution to maintain compound integrity.
• Verify concentration and purity by HPLC or NMR, as provided by APExBIO, to ensure reproducibility.
• Integrate multi-system endpoints (gastric, hepatic, CNS) and advanced imaging modalities (e.g., PET with TSPO tracers) for comprehensive data sets.
• Monitor gut microbiome changes when employing the compound chronically, as part of gut–brain axis research.

Broader Implications and Future Directions

The use of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is poised to extend far beyond traditional antiulcer research. By enabling precise, titratable inhibition of the proton pump, it becomes a gateway for probing the mechanistic links between gastric acid secretion, microbial ecology, systemic inflammation, and CNS health. This compound is especially valuable in the era of multi-omics and systems biology, where subtle perturbations in gastric physiology can be correlated with downstream effects in distant organs.

As research on the gut–liver–brain axis deepens—supported by innovations in in vivo imaging and molecular profiling—the ability to selectively manipulate gastric acid secretion with a tool as robust as A2845 will be indispensable. This article thus provides a unique translational perspective, building on but distinctly diverging from previous content that emphasized either stepwise protocols or narrow laboratory troubleshooting.

Conclusion and Future Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845, APExBIO) stands at the intersection of high-precision gastric acid secretion research and emerging neuroinflammation studies. Its superior selectivity, potency, and chemical profile make it an essential molecule for antiulcer activity studies, peptic ulcer disease modeling, and probing the proton pump inhibition pathway. More importantly, its application in holistic disease models that bridge gastroenterology and neuroscience places it on the frontier of translational research. For scientists seeking to go beyond traditional boundaries—integrating gastric, microbial, hepatic, and CNS endpoints—A2845 represents a new era in experimental investigation.

For further information or to order, visit the official product page for 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide.